INS and Hyperglycemia: Based on this glucose profile and the use of insulin, the Onduo endocrinologist made the following changes on day 27: the sulfonylurea (glipizide) was discontinued due to concurrent insulin use and the DPP-4 inhibitor (sitagliptin) was discontinued and exchanged for a GLP-1 receptor agonist (liraglutide) to address hyperglycemia.